Literature DB >> 22249643

Adolescent female with withdrawal psychosis following abrupt termination of ziprasidone.

Maryann K Jacob1, Peter Ash, W Edward Craighead.   

Abstract

It is widely known that discontinuation reactions can occur after neuroleptics are stopped resulting in dyskinesia through its effect on the nigrostriatal pathway. Less discussed is the concept of "supersensitivity psychosis" which has been described as a rapid onset of psychosis after a neuroleptic medication has been withdrawn. Although the concept of supersensitivity psychosis has been described with the discontinuation of some neuroleptics, it has not been described with ziprasidone. Furthermore, the following case report is the first time that this phenomenon has been described in an adolescent patient who has discontinued ziprasidone. Reasons for supersensitivity psychosis are explored in addition to suggestions about precautions about prescribing neuroleptics in young people.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22249643     DOI: 10.1007/s00787-012-0239-z

Source DB:  PubMed          Journal:  Eur Child Adolesc Psychiatry        ISSN: 1018-8827            Impact factor:   4.785


  15 in total

1.  Supersensitivity psychosis in patients with schizophrenia after sudden olanzapine withdrawal.

Authors:  P M Llorca; G Vaiva; C Lancon
Journal:  Can J Psychiatry       Date:  2001-02       Impact factor: 4.356

Review 2.  The effect of chronic neuroleptic administration on cerebral dopamine receptor function.

Authors:  M N Rupniak; P Jenner; C D Marsden
Journal:  Life Sci       Date:  1983-05-16       Impact factor: 5.037

3.  Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics.

Authors:  G Chouinard; B D Jones
Journal:  Am J Psychiatry       Date:  1980-01       Impact factor: 18.112

Review 4.  Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse.

Authors:  J Moncrieff
Journal:  Acta Psychiatr Scand       Date:  2006-07       Impact factor: 6.392

5.  Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients.

Authors:  M A Richardson; G Haugland; T J Craig
Journal:  Am J Psychiatry       Date:  1991-10       Impact factor: 18.112

6.  Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment.

Authors:  G Chouinard
Journal:  Schizophr Res       Date:  1991 Jul-Aug       Impact factor: 4.939

7.  Development and validation of a high-sensitivity assay for an antipsychotic agent, CP-88,059, with solid-phase extraction and narrow-bore high-performance liquid chromatography.

Authors:  J S Janiszewski; H G Fouda; R O Cole
Journal:  J Chromatogr B Biomed Appl       Date:  1995-06-09

8.  Withdrawal from clozapine: the "rebound phenomenon".

Authors:  R Durst; A Teitelbaum; G Katz; H Y Knobler
Journal:  Isr J Psychiatry Relat Sci       Date:  1999       Impact factor: 0.481

9.  Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder.

Authors:  Howard C Margolese; Guy Chouinard; Linda Beauclair; Marie-Claire Bélanger
Journal:  J Clin Psychopharmacol       Date:  2002-08       Impact factor: 3.153

10.  Metoclopramide-induced supersensitivity psychosis.

Authors:  Mong-Liang Lu; Jan-Jhy Pan; Hui-Wen Teng; Kuan-Pin Su; Winston W Shen
Journal:  Ann Pharmacother       Date:  2002-09       Impact factor: 3.154

View more
  3 in total

1.  Aripiprazole withdrawal: a case report.

Authors:  Randy A Sansone; Robert J Sawyer
Journal:  Innov Clin Neurosci       Date:  2013-05

2.  A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse.

Authors:  Mark Abie Horowitz; Sameer Jauhar; Sridhar Natesan; Robin M Murray; David Taylor
Journal:  Schizophr Bull       Date:  2021-07-08       Impact factor: 7.348

3.  Supersensitivity psychosis and its response to asenapine in a patient with delusional disorder.

Authors:  Ravi Philip Rajkumar
Journal:  Case Rep Psychiatry       Date:  2014-11-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.